GLP-1 Receptor Agonists in Diabetic Kidney Disease.
作者信息
Michos Erin D, Tuttle Katherine R
机构信息
Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Providence Medical Research Center, Providence Health Care, Spokane, Washington.
出版信息
Clin J Am Soc Nephrol. 2021 Oct;16(10):1578-1580. doi: 10.2215/CJN.18771220. Epub 2021 Apr 13.
Abstract
摘要
相似文献
1
GLP-1 Receptor Agonists in Diabetic Kidney Disease.糖尿病肾病中的胰高血糖素样肽-1受体激动剂
Clin J Am Soc Nephrol. 2021 Oct;16(10):1578-1580. doi: 10.2215/CJN.18771220. Epub 2021 Apr 13.
2
Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.胰高血糖素样肽-1 受体激动剂治疗慢性肾脏病伴 2 型糖尿病患者的疗效及其对肾脏的影响评价。
J Diabetes. 2019 Dec;11(12):938-948. doi: 10.1111/1753-0407.12969. Epub 2019 Aug 14.
3
Effects of Diabetes Medications Targeting the Incretin System on the Kidney.靶向肠促胰岛素系统的糖尿病药物对肾脏的影响。
Clin J Am Soc Nephrol. 2018 Feb 7;13(2):321-323. doi: 10.2215/CJN.10380917. Epub 2018 Jan 10.
4
Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment.胰高血糖素样肽-1 受体激动剂和钠-葡萄糖共转运蛋白 2 抑制剂对伴有肾功能损害的 2 型糖尿病患者的影响。
Diab Vasc Dis Res. 2020 Nov-Dec;17(6):1479164120971220. doi: 10.1177/1479164120971220.
5
Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.利拉鲁肽治疗 2 型糖尿病合并慢性肾脏病的安全性。
Clin J Am Soc Nephrol. 2020 Apr 7;15(4):465-473. doi: 10.2215/CJN.11881019. Epub 2020 Mar 4.
6
Potential kidney protective effects of glucagon-like peptide-1 receptor agonists.胰高血糖素样肽-1 受体激动剂的潜在肾脏保护作用。
Nephrology (Carlton). 2024 Aug;29(8):457-469. doi: 10.1111/nep.14336. Epub 2024 Jun 20.
7
Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.钠-葡萄糖协同转运蛋白2抑制剂卡格列净对2型糖尿病合并慢性肾脏病患者的肾脏保护作用：一项随机开放标签前瞻性试验。
Diab Vasc Dis Res. 2018 Sep;15(5):469-472. doi: 10.1177/1479164118782872. Epub 2018 Jun 20.
8
Glucagon-like peptide-1 receptor agonists and kidney outcomes.胰高血糖素样肽-1 受体激动剂与肾脏结局。
J Diabetes. 2024 Oct;16(10):e13609. doi: 10.1111/1753-0407.13609.
9
GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side.GLP-1 受体激动剂在糖尿病肾病中的应用：从患者角度到实验研究。
Am J Physiol Renal Physiol. 2018 Dec 1;315(6):F1519-F1525. doi: 10.1152/ajprenal.00211.2018. Epub 2018 Aug 15.
10
Diagnosis and Management of Type 2 Diabetic Kidney Disease.2型糖尿病肾病的诊断与管理
Clin J Am Soc Nephrol. 2017 Aug 7;12(8):1366-1373. doi: 10.2215/CJN.11111016. Epub 2017 Mar 9.
引用本文的文献
1
Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs.慢性肾脏病中糖尿病治疗药物的重新利用：钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂的作用机制、临床疗效及安全性
Pharmaceuticals (Basel). 2025 Jul 28;18(8):1130. doi: 10.3390/ph18081130.
2
The dual GLP-1 and GIP receptor agonist tirzapetide provides an unintended interaction with the β-adrenoceptors and plays a role in glucose metabolism in hyperglycemic or senescent cardiac cells.双重GLP-1和GIP受体激动剂替尔泊肽与β-肾上腺素能受体产生意外相互作用，并在高血糖或衰老心肌细胞的葡萄糖代谢中发挥作用。
Cardiovasc Diabetol. 2025 Aug 18;24(1):338. doi: 10.1186/s12933-025-02828-z.
3
Exploring Liraglutide's mechanism in reducing renal fibrosis: the Fsp1-CoQ10-NAD(P)H pathway.探索利拉鲁肽减轻肾纤维化的机制：Fsp1-辅酶Q10-NAD(P)H途径
Sci Rep. 2025 Jan 12;15(1):1754. doi: 10.1038/s41598-025-85658-z.
4
Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic Disorders.胰高血糖素样肽-1（GLP-1）激动剂在2型糖尿病及相关代谢紊乱管理中的最新进展和治疗益处
Cureus. 2024 Oct 21;16(10):e72080. doi: 10.7759/cureus.72080. eCollection 2024 Oct.
5
Treatment of Podocytopathies: Risky Business and Our Personal Journey.足细胞病的治疗：充满风险的事务与我们的个人历程
J Am Soc Nephrol. 2024 Nov 1;35(11):1600-1602. doi: 10.1681/ASN.0000000000000415. Epub 2024 May 15.
6
Exploring the clinical effectiveness of glucagon-like peptide-1 receptor agonists in managing cardiovascular complications: an updated comprehensive review and future directives.探索胰高血糖素样肽-1受体激动剂在管理心血管并发症方面的临床疗效：最新综合综述及未来指导意见。
Ann Med Surg (Lond). 2024 Aug 22;86(10):5947-5956. doi: 10.1097/MS9.0000000000002494. eCollection 2024 Oct.
7
Chronic Kidney Disease in Brazil: Current Status and Recommended Improvements.巴西的慢性肾脏病：现状与建议改进措施
Kidney Dis (Basel). 2024 Feb 29;10(3):213-223. doi: 10.1159/000538068. eCollection 2024 Jun.
8
Efficacy and safety of finerenone in chronic kidney disease and type 2 diabetes patients: a systematic review and meta-analysis.非奈利酮在慢性肾脏病和2型糖尿病患者中的疗效与安全性：一项系统评价和荟萃分析
Ann Med Surg (Lond). 2023 Aug 16;85(10):4973-4980. doi: 10.1097/MS9.0000000000001180. eCollection 2023 Oct.
9
Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection.胰高血糖素样肽-1受体激动剂在糖尿病肾病中的应用：肾脏与心脏保护作用综述
Am J Prev Cardiol. 2023 May 24;14:100502. doi: 10.1016/j.ajpc.2023.100502. eCollection 2023 Jun.
10
Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney disease.靶向药物递送策略：通向糖尿病肾病治疗的桥梁。
Drug Deliv. 2023 Dec;30(1):2160518. doi: 10.1080/10717544.2022.2160518.
Zotero 插件